GSK 2696273

Drug Profile

GSK 2696273

Alternative Names: 2696273; Adenosine deaminase severe combined immune deficiency therapy - GlaxoSmithKline; GSK-2696273; Strimvelis

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator The San Raffaele Telethon Institute for Gene Therapy
  • Developer GlaxoSmithKline
  • Class Gene therapies; Stem cell therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adenosine deaminase deficiency
  • New Molecular Entity No

Highest Development Phases

  • Registered Adenosine deaminase deficiency

Most Recent Events

  • 23 Oct 2017 The National Institute for Health and Care Excellence (NICE) approves GSK 2696273 in Adenosine deaminase deficiency in the United Kingdom
  • 27 May 2016 Registered for Adenosine deaminase deficiency in European Union (Intraosseous) - First global approval
  • 27 May 2016 Registered for Adenosine deaminase deficiency in Liechtenstein, Iceland, Norway (Intraosseous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top